Pfizer

Recent news

• J.P. Morgan Keeps Their Hold Rating on Pfizer (PFE)
  TipRanks · 2026/10/9
• A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $28 to $36
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Cantor Fitzgerald Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $28
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• Rating change
  BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• Rating change
  Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• Rating change
  Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Company notice
  Pfizer | 4: Statement of changes in beneficial ownership of securities-Director LITTMAN DAN R.
  SEC · 2026/4/28
• Company notice
  Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer DAMICO JENNIFER B.
  SEC · 2026/3/4
• Rating change
  Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Raises Target Price to $35
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Rating change
  Scotiabank Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• BofA Securities Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $29
  \u5e02\u573a\u8d44\u8baf · 2026/10/10
• Company notice
  Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer DAMICO JENNIFER B.
  SEC · 2026/2/28
• Company notice
  Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer DAMICO JENNIFER B.
  SEC · 2026/3/6
• Rating change
  Morgan Stanley Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Company notice
  Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer DAMICO JENNIFER B.
  SEC · 2026/6/11
• Rating change
  Scotiabank Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Rating change
  HSBC Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• Rating change
  Scotiabank Maintains Pfizer(PFE.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Rating change
  Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $28
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• Rating change
  Barclays Maintains Pfizer(PFE.US) With Sell Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• Rating change
  Scotiabank Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• Pfizer, BioNTech, and Moderna sought to have Bayer's Monsanto mRNA patent lawsuit dismissed, but the judge rejected their motion.
  Zhitong Finance · 2026/9/29
• Rating change
  Cantor Fitzgerald Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• Rating change
  Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $31
  \u5e02\u573a\u8d44\u8baf · 2026/8/7

Headlines are aggregated automatically and are not independently verified or edited by our team.